Oncology Brothers· @OncBrothers · X·· 2 days agoScore70
Body · original
IO + EV upfront is now the SoC for MIBC!! But how much EV do we need in postOP settings? Eagerly looking forward to more data/discussion on Day 2 #ESMO26! VOLGA as the new SoC!!??!!
#gusm @myESMO #BladderCancer
330 views · 3 likes · 4 reposts · 0 replies
Conference abstracts
LBA2matched by Presidential Symposium I
Perioperative durvalumab with or without tremelimumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer: Results from the phase 3 VOLGA trial
https://esmocongress.esmo.orgVOLGA
https://esmocongress.esmo.orgESMO 2026 - presidential LBA | VOLGA Phase III – Perioperative Durvalumab + Enfortumab Vedotin (EV) in cisplatin-ineligible/refusing patients: 📊 EV + Durva vs Control • 2-year EFS: 64% vs 45% (HR 0.51; p<0.0001) • 2-year OS: 78% vs 69% (HR 0.58; p=0.0027) • pCR: 45% vs 10% Adding tremelimumab improved EFS (HR 0.61) but no significant OS benefit yet, with higher grade 3/4 toxicity (42% vs 30%). 🔥can this stop the need of post op EV ? Probably yes . New SOC 🙂👍 Looking forward the full datasets @OncBrothers @OncoAlert @myESMO #ESMO26 #VOLGA #BladderCancer在 X 查看被引用的帖子
Source: Oncology Brothers · x.com